A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)

Author(s):
Krajewska, J.; Robinson, B.G.; Keam, B.; Capdevila, J.; Klochikhin, A.; Gan, H.; Kapiteijn, E.; Elisei, R.; Partyka, J.; Borgman, A.E.; Schlumberger, M.
Published
2018
Publication type
Other
Date issued
2018-10-01
Language
English
Publisher
OXFORD UNIV PRESS
hdl
1887/122834